Summary sheet
Coloplast A/S
The project concerns the promoter’s research, development and innovation (RDI) activities within its Ostomy Care, Urology/Continence Care and Wound and Skin Care divisions targeting novel innovative product platforms and product improvements. The promoter aims to half the time to market and more than double its pipeline value by 2011, mainly by reaping synergies between different business areas; the implementation of this strategy will impact the present project. The project will be implemented in the period 2008-2010.
The project should strengthen the market position of a medium-sized EU-based niche player, operating in the segmented global market for medical care products and services.
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An EIA therefore is not required by EU Directive 97/11 as amended by Directive 2003/35. Compliance of R&D activities with relevant EU environmental legislation will be verified during appraisal.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU directives on procurement.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications